Recent Updates
Recently added Catalysts
GRAL Positive Sentiment

GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Key Takeaway: GRAIL, Inc. has announced the granting of equity awards in the form of restricted stock units to 21 new non-executive employees as part of its Inducement Equity Incentive Plan. This initiative aims to attract talent and is compliant with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, promoting long-term commitment to the company.
Price reaction · baseline $98.27 (2025-12-01 close) · hit after-hours · clean, no other GRAL news in the window
day 0 close
-0.9%

Market Sentiment Analysis

POSITIVE FACTORS

  • GRAIL is expanding its workforce with new hires.
  • The equity awards incentivize employees to join GRAIL.
  • The company's mission focuses on early cancer detection.

Full Press Release Details

MENLO PARK, Calif.,Dec. 1, 2025/PRNewswire/ -- GRAIL, Inc. (Nasdaq:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has granted equity awards in the form of restricted stock units ("RSUs") underlying an aggregate of 21,570 shares of GRAIL's common stock to 21 recently hired non-executive employees as an inducement material to their acceptance of employment with GRAIL. The employment inducement awards were granted under GRAIL's Inducement Equity Incentive Plan and related form of restricted stock award agreement in accordance with Nasdaq Listing Rule 5635(c)(4).
The inducement plan is used exclusively for the grant of equity awards to individuals who were not previously employees of GRAIL, or following a bona fide period of non-employment, as an inducement material to such individuals entering into employment with GRAIL, pursuant to Nasdaq Listing Rule 5635(c)(4).
The RSUs vest over an approximately four year period, with 25% of the award vesting Nov. 30, 2026, and on each one year anniversary of those respective dates thereafter, subject to continued employment with GRAIL (or any successor to or subsidiary of the Company) through the vesting dates.
About GRAILGRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL's targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in Menlo Park, CA with locations in Washington, D.C., North Carolina, and the United Kingdom.
For more information, visitgrail.com.

Frequently Asked Questions

What are the inducement grants by GRAIL?

GRAIL has granted equity awards in the form of restricted stock units to new hires.

How many employees received equity awards?

21 recently hired non-executive employees received the equity awards.

What is the vesting period for the RSUs?

The RSUs vest over approximately four years, starting with 25% on Nov. 30, 2026.

What is GRAIL's mission?

GRAIL aims to detect cancer early when it can be cured, using advanced technology.

Last updated: Dec 1, 2025